Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6091309 | Clinical Gastroenterology and Hepatology | 2015 | 8 Pages |
Abstract
Cessation of lamivudine therapy after recovery from hepatitis B flare with decompensation was safe for most patients. However, 8.2% develop decompensation within 1 year and can be rescued by timely retreatment. With close monitoring, the stopping strategy could be a feasible alternative to indefinite therapy, especially in low resource settings.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Ming-Ling Chang, Wen-Juei Jeng, Yun-Fan Liaw,